LifeSci Capital Maintains Buy Rating on Kura Oncology (KURA)

Kura Oncology, Inc. (NASDAQ:KURA) is one of the Top 10 Stocks Under $10 That Could Triple. On September 1, TipRanks reported that Charles Zhu from LifeSci Capital reiterated a Buy rating on Kura Oncology, Inc. (NASDAQ:KURA) with a $24 price target.

This decision reflects the potential of Kura Oncology, Inc.’s (NASDAQ:KURA) drug candidate KO-2806 in treating clear cell renal cell carcinoma (ccRCC). The upcoming presentations at ESMO 2025, especially the combination of KO-2806 with cabozantinib, could prove to be important opportunities to show that this treatment is both safe and effective.

Although farnesyl transferase inhibitors (FTIs) have faced many challenges in the past, KO-2806 could stand out. Its mechanistic similarities with mTORC1 inhibitors and its potential for improved tolerability make it a promising candidate.

Additionally, there is strong potential for Kura Oncology, Inc.’s (NASDAQ:KURA) KO-2806 to reach a 40% objective response rate (ORR) in combination with cabozantinib. This potential is more promising compared to current treatments.

The market seems to have overlooked this opportunity as Kura Oncology, Inc. (NASDAQ:KURA) is currently trading at a low enterprise value. There could be a strong upside if the clinical data can confirm the drug’s effectiveness.

Kura Oncology, Inc. (NASDAQ:KURA) is a clinical-stage biopharmaceutical company focused on developing targeted, well-tolerated treatments for cancer.

While we acknowledge the potential of KURA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Hot Mid Cap Stocks to Buy Now and 10 Best Affordable Stocks Under $50 to Buy.

Disclosure: None. This article is originally published at Insider Monkey.